These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 3257143

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.
    Meany HJ, Seibel NL, Krailo M, Villaluna D, Chen Z, Gaynon P, Neglia JP, Park JR, Hutchinson R, Sato JK, Wells RJ, Woods WG, Reaman G.
    J Immunother; 2015 Sep; 38(7):299-305. PubMed ID: 26261894
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Biphenotypic leukemic lymphocyte precursors in CD2+CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues.
    Uckun FM, Muraguchi A, Ledbetter JA, Kishimoto T, O'Brien RT, Roloff JS, Gajl-Peczalska K, Provisor A, Koller B.
    Blood; 1989 Mar; 73(4):1000-15. PubMed ID: 2784064
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Regulatory role of CD19 molecules in B-cell activation and differentiation.
    de Rie MA, Schumacher TN, van Schijndel GM, van Lier RA, Miedema F.
    Cell Immunol; 1989 Feb; 118(2):368-81. PubMed ID: 2463100
    [Abstract] [Full Text] [Related]

  • 27. Analysis of the individual and combined reactivities of monoclonal antibodies H25, H366, and MY9 with normal progenitor cells and blast cells from patients with acute myeloblastic leukemia.
    Wisniewski D, Strife A, Arlin Z, Knowles R, Lambek C, Gulati S, McHendry B, McKenzie S, Clarkson B.
    Leukemia; 1989 Jun; 3(6):446-52. PubMed ID: 2657231
    [Abstract] [Full Text] [Related]

  • 28. Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule.
    Myers DE, Yanishevski Y, Masson E, Irvin JD, Evans WE, Uckun FM.
    Leuk Lymphoma; 1995 Jun; 18(1-2):93-102. PubMed ID: 8580835
    [Abstract] [Full Text] [Related]

  • 29. Use of colony assays and anti-T cell immunotoxins to elucidate the immunobiologic features of leukemic progenitor cells in T-lineage acute lymphoblastic leukemia.
    Uckun FM, Myers DE, Ledbetter JA, Swaim SE, Gajl-Peczalska KJ, Vallera DA.
    J Immunol; 1988 Mar 15; 140(6):2103-11. PubMed ID: 3126241
    [Abstract] [Full Text] [Related]

  • 30. Effects of low molecular weight B-cell growth factor on proliferation of leukemic cells from children with B-cell precursor-acute lymphoblastic leukemia.
    Findley HW, Zhou MX, Davis R, Abdul-Rahim Y, Hnath R, Ragab AH.
    Blood; 1990 Feb 15; 75(4):951-7. PubMed ID: 2302462
    [Abstract] [Full Text] [Related]

  • 31. B8.7 antigen is present on B-cell precursor acute lymphocytic leukemia. Correlation with the low molecular weight B-cell growth factor responsiveness of these cells.
    Leprince C, Blumenfeld N, Flandrin G, Galanaud P, Sigaux F, Richard Y.
    Blood; 1990 Feb 15; 75(4):963-71. PubMed ID: 2137354
    [Abstract] [Full Text] [Related]

  • 32. Malignant human B cells express two populations of p24 surface antigens.
    Pesando JM, Hoffman P, Conrad T.
    J Immunol; 1986 Apr 01; 136(7):2709-14. PubMed ID: 3485154
    [Abstract] [Full Text] [Related]

  • 33. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor.
    Uckun FM, Messinger Y, Chen CL, O'Neill K, Myers DE, Goldman F, Hurvitz C, Casper JT, Levine A.
    Clin Cancer Res; 1999 Dec 01; 5(12):3906-13. PubMed ID: 10632319
    [Abstract] [Full Text] [Related]

  • 34. Large scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma.
    Myers DE, Sicheneder A, Clementson D, Dvorak N, Venkatachalam T, Sev AR, Chandan-Langlie M, Uckun FM.
    Leuk Lymphoma; 1998 Apr 01; 29(3-4):329-38. PubMed ID: 9684930
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Fc gamma receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody.
    Vervoordeldonk SF, Merle PA, van Leeuwen EF, van der Schoot CE, von dem Borne AE, Slaper-Cortenbach IC.
    Blood; 1994 Mar 15; 83(6):1632-9. PubMed ID: 7510146
    [Abstract] [Full Text] [Related]

  • 39. Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin.
    Roy DC, Perreault C, Bélanger R, Gyger M, Le Houillier C, Blättler WA, Lambert JM, Ritz J.
    J Clin Immunol; 1995 Jan 15; 15(1):51-7. PubMed ID: 7539011
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.